(Q46398147)
Statements
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels (English)
Donna L Forrest
Shannon Trainor
Michael J Barnett
Donna E Hogge
Thomas J Nevill
John D Shepherd
Stephen H Nantel
Cynthia L Toze
Heather J Sutherland
Kevin W Song
Julye C Lavoie
Maryse M Power
Yasser Abou-Mourad
Clayton A Smith
31 August 2008